| Literature DB >> 34869080 |
Di Deng1, Hang Su1, Yuehong Song1, Tianzhen Chen1, Qianqian Sun1, Haifeng Jiang1, Min Zhao1,2,3.
Abstract
Methamphetamine use disorder (MUD) is a major public health problem worldwide with limited effective treatment options. Previous studies have reported methamphetamine-associated alterations in gut microbiota. A potential role of gut microbiota in regulating methamphetamine-induced brain dysfunction through interactions with the host immune system has been proposed, but evidence for this hypothesis is limited. The present study aimed to investigate the alterations in the fecal microbiota and explore its relationship with systemic inflammation in MUD. Fecal samples were obtained from 26 male subjects with MUD and 17 sex- and age- matched healthy controls. Fecal microbial profiles were analyzed by 16S rRNA sequencing. Plasma inflammatory markers were measured using enzyme-linked immunosorbent assay. Associations between fecal microbiota, systemic inflammatory markers and clinical characteristics were examined by Spearman partial correlation analysis while controlling for possible confounders. Compared with healthy controls, individuals with MUD showed no difference in fecal microbial diversity, but exhibited differences in the relative abundance of several microbial taxa. At the genus level, a higher abundance of Collinsella, Odoribacter and Megasphaera and lower levels of Faecalibacterium, Blautia, Dorea and Streptococcus were detected in subjects with MUD. More importantly, altered fecal microbiota was found to be correlated with plasma levels of CRP, IL-2, IL-6 and IL-10. The order Lactobacillales, exhibiting lower abundance in participants with MUD, was positively related to the duration of methamphetamine abstinence and the plasma level of anti-inflammatory cytokine IL-10. This study is the first to provide evidence for a link between altered fecal microbiota and systemic inflammation in MUD. Further elucidation of interactions between gut microbiota and the host immune system may be beneficial for the development of novel therapeutic approaches for MUD.Entities:
Keywords: 16S rRNA sequence; gut microbiota; gut-immune-brain; methamphetamine use disorder; systemic inflammation
Mesh:
Substances:
Year: 2021 PMID: 34869080 PMCID: PMC8637621 DOI: 10.3389/fcimb.2021.783917
Source DB: PubMed Journal: Front Cell Infect Microbiol ISSN: 2235-2988 Impact factor: 5.293
Demographic and clinical characteristics of study participants.
| Characteristics | MUD group (N = 26) | HC group (N = 17) | P-value |
|---|---|---|---|
| Age, years | 33.34 [31.80-38.17] | 34.00 [26.5-55.5] | 0.619a |
| BMI, kg/m2 | 24.92 ± 3.06 | 23.63 ± 3.73 | 0.222b |
| Education, years | 12 [9-14.25] | 16 [9-17] | 0.188a |
| Married, N (%) | 7 (26.9%) | 10 (58.8%) | 0.036c |
| Employed, N (%) | 21 (80.8%) | 17 (100%) | 0.139d |
| AUDIT | 9 [0-13.25] | 0 [0-0] | <0.001a |
| FTND | 5 [2.75-6] | 0 [0-1] | <0.001a |
|
| |||
| Age of first use | 27.47 ± 5.33 | NA | NA |
| Total years of use | 4 [3-7] | NA | NA |
| Months of abstinence | 8.22 [3.38-16.04] | NA | NA |
| Frequency of use (in last month before rehabilitation) | NA | ||
| Almost everyday | 0 (0%) | – | |
| 3-5 times a week | 4 (15.4%) | – | |
| 1-2 times a week | 8 (30.8%) | – | |
| Less than once a week | 14 (53.8%) | – | |
| Craving (VAS) | 2 [0.5-4.35] | – | |
|
| |||
| PHQ-9 | 3 [0.75-5] | – | NA |
| GAD-7 | 1 [0-4.25] | – | NA |
|
| |||
| CRP, mg/L | 7.72 ± 1.66 | – | NA |
| TNF-α, pg/mL | 69.88 ± 12.11 | – | NA |
| IL-2, ng/mL | 6.84 ± 1.50 | – | NA |
| IL-6, pg/mL | 27.01 ± 7.41 | – | NA |
| IL-10, pg/mL | 937.21 ± 169.26 | – | NA |
Data are presented as mean ± standard deviation (SD), Median [IQR, inter-quartile range], or N (%). ap values based on Mann-Whitney U test; bp values based on Student’s t test; cp values based on Pearson chi-square test; dp values based on Fisher exact test. MUD, methamphetamine use disorder; HC, healthy control; BMI, body mass index, calculated as weight in kilograms divided by height in meters squared; AUDIT= Alcohol Use Disorders Identification Test; FTND, Fagerstrom Test for Nicotine Dependence; NA, not applicable; VAS, Visual Analogue Scale; PHQ-9, Patient Health Questionnaire-9; GAD-7, General Anxiety Disorder Scale-7; CRP, C-reactive protein; TNF-α, Tumor necrosis factor-alpha; IL, Interleukin.
Figure 1Taxa with significant different abundance between the MUD and HC groups. (A) Taxonomic cladogram obtained from LEfSe analysis displaying differentially enriched bacterial taxa in HC (red) and MUD (green). (B) Linear discriminant analysis (LDA) revealed the effect size of each differentially abundant taxa (LDA score > 2, p < 0.05).
Figure 2Barplots for relative abundance of significantly different taxa identified by LEfSe in the two groups. The x-axis represents the means proportion of the taxa. Each bar shows mean ± SEM. aThe taxa showed the same relative abundance at both taxa levels.
Detection of taxa significantly associated with MUD by MaAsLin2.
| Taxa | Model 1 (unadjusted) | Model 2 (adjusted for age, BMI, AUDIT score, and FTND score) | ||||
|---|---|---|---|---|---|---|
| Coef.# | p value | q value | Coef.# | p value | q value | |
|
| 0.0254 | 0.1014 | 0.6085 | 0.0626 | 0.0060 |
|
|
| -0.0135 | 0.0002 | 0.0018** | -0.0134 | 0.0128 |
|
| p:Proteobacteria;c:Betaproteobacteria | 0.0386 | 0.0346 | 0.1903* | 0.0207 | 0.4583 | 0.7180 |
|
| 0.0255 | 0.1005 | 0.2762 | 0.0629 | 0.0058 |
|
|
| -0.0138 | 0.0002 | 0.0021** | -0.0139 | 0.0107 |
|
|
| 0.0215 | 0.0123 | 0.0796* | 0.0557 | 5.94E-07 |
|
| p:Proteobacteria; c:Betaproteobacteria; o:Burkholderiales | 0.0386 | 0.0345 | 0.1496* | 0.0208 | 0.4569 | 0.6906 |
| p:Firmicutes; c:Bacilli; o:Lactobacillales; f:Streptococcaceae | -0.0098 | 0.0047 | 0.0858* | -0.0110 | 0.0312 | 0.4957 |
|
| 0.0220 | 0.0127 | 0.0858* | 0.0575 | 5.52E-07 |
|
| p:Firmicutes; c:Clostridia; o:Clostridiales; f:Clostridiaceae1 | -0.0290 | 0.0129 | 0.0858* | -0.0322 | 0.0651 | 0.5099 |
| p:Firmicutes; c:Clostridia; o:Clostridiales; f:Lachnospiraceae; g:Blautia | -0.0338 | 0.0011 | 0.0539* | -0.0237 | 0.1234 | 0.6760 |
| p:Firmicutes; c:Clostridia; o:Clostridiales; f:Ruminococcaceae; g:Faecalibacterium | -0.1369 | 0.0049 | 0.1045* | -0.0874 | 0.2228 | 0.6853 |
|
| 0.0275 | 0.0061 | 0.1045* | 0.0664 | 6.11E-07 |
|
| p:Firmicutes; c:Clostridia; o:Clostridiales; f:Clostridiaceae1; g:Clostridium sensu stricto | -0.0317 | 0.0127 | 0.1625* | -0.0365 | 0.0579 | 0.5473 |
|
| 0.0223 | 0.0232 | 0.2202* | 0.0474 | 0.0016 |
|
| p:Firmicutes; c:Clostridia; o:Clostridiales; f:Lachnospiraceae; g:Dorea | -0.0207 | 0.0295 | 0.2202* | -0.0147 | 0.3240 | 0.7311 |
| p:Firmicutes; c:Bacilli; o:Lactobacillales; f:Streptococcaceae; g:Streptococcus | -0.0084 | 0.0302 | 0.2202* | -0.0083 | 0.1406 | 0.6766 |
#Coefficients from the generalized linear model using MaAsLin2 on pairwise testing between the two groups. *q < 0.25; **q < 0.05; q values were calculated using Benjamin-Hochberg correction (FDR). In Model 2, taxa with significant difference and their q values were bolded. p, phylum; c, class; o, order; f, family; g, genus.
Correlations between altered fecal microbiota, clinical variables and markers of systemic inflammation. .
| Interactions between variables | Correlation coefficient (r) | p value | q value | |
|---|---|---|---|---|
|
| ||||
| Age of First Use | p:Actinobacteria; c:Actinobacteria# | -0.4853 | 0.0221 |
|
| o:Coriobacteriales; f:Coriobacteriaceae# | -0.5638 | 0.0063 |
| |
| g:Collinsella | -0.5181 | 0.0135 |
| |
| g:Blautia | -0.6656 | 0.0007 |
| |
| Total Years of Use | o:Coriobacteriales; f:Coriobacteriaceae# | 0.5666 | 0.0060 |
|
| g:Collinsella | 0.5312 | 0.0110 |
| |
| g:Blautia | 0.4395 | 0.0407 |
| |
| Months of Abstinence | o:Lactobacillales | 0.4233 | 0.0496 |
|
|
| ||||
| CRP | g:Megasphaera | 0.5221 | 0.0127 |
|
| IL-6 | p:Actinobacteria; c:Actinobacteria# | -0.4501 | 0.0356 |
|
| g:Dorea | 0.5244 | 0.0122 |
| |
| IL-10 | c:Bacilli | 0.4529 | 0.0343 |
|
| o:Lactobacillales | 0.4660 | 0.0288 |
| |
| f:Streptococaceae; g:Streptococcus# | 0.5137 | 0.0145 |
| |
| IL-2 | g:Blautia | 0.5069 | 0.0161 |
|
|
| ||||
| Age of First Use | IL-2 | -0.4394 | 0.0408 |
|
| IL-10 | -0.4252 | 0.0485 |
| |
| Frequency of Use | CRP | -0.4438 | 0.0385 |
|
| IL-6 | -0.4270 | 0.0475 |
| |
| Craving | CRP | -0.5003 | 0.0177 |
|
| IL-10 | 0.4408 | 0.0401 |
| |
| GAD-7 | IL-10 | -0.4667 | 0.0285 |
|
Spearman partial correlation adjusting for age, BMI, AUDIT score, and FTND score (N =26). Q values were calculated using Benjamin-Hochberg correction (FDR); q values < 0.05 were bolded. #The taxa showed the same relative abundance at both taxa levels. c, class; o, order; f, family; g, genus; CRP, C-reactive protein; IL, Interleukin; GAD-7, General Anxiety Disorder Scale-7.
Figure 3Connections between altered fecal microbiota, clinical variables and systemic inflammation identified by Spearman partial correlation. Adjusted for age, BMI, AUDIT score, and FTND score. Only significant correlations with an FDR q value < 0.05 were shown. #The taxa showed the same relative abundance at both taxa levels. c, class; o, order; f, family; g, genus; CRP, C-reactive protein; IL, Interleukin; GAD-7, General Anxiety Disorder Scale-7.